Main Menu

A hybridoma cell line producing a monoclonal hamster antibody specific to mouse CD51 (vitronectin receptor, alpha chain) (clone H9.2B8) as described in J Exp Med. 1989 Jun 1;169(6):2173-90 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.

Hybridoma Cell Line B6GE1 as described in Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13856-61 and developed in the laboratory of Dr. Ronald Germain.

An H-2Kb/OVA hybridoma cell line producing a monoclonal antibody specific for the H-2Kb/SIINFEKL complex (clone 25-D1.16) as described in Immunity 1997 Jun;6(6):715-26 and developed in the laboratory of Dr. Ronald Germain at the National Institute of Allergy and Infectious Diseases.

A murine hybridoma expressing mAb BD3 was found to react with a conformationally dependent epitope on the chlamydial Major Outer Membrane Protein (MOMP), a primary target of neutralizing antibodies and vaccine development. The BD3 neutralized the in vitro infectivity of C. trachomatis serovars B, Ba, D, E, L2. It is useful for verifying the correct conformation of MOMP in vaccines against chlamydia trachomatis, Serovars B, BA, D, E, AND L2.

Hybridoma Cell Line D8H21, as described in Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13856-61 and developed in the laboratory of Dr. Ronald Germain.

RGS13, an intracellular protein in mast cells, was shown to suppress IgE-mediated anaphylactic response in mice. The RGS13-/- mouse may be used to screen compounds that inhibit mast cell degranulation.

NIAID has a hybridoma available for non-exclusive licensing that produces a monoclonal antibody specific for DNA/RNA hybrids. This antibody, which has been extensively characterized by NIH researchers, is already a widely-used research tool. It is currently the only monoclonal antibody available that is specific for DNA/RNA hybrids, making it a unique reagent. It is used in immuno-fluorescence (IF) microscopy, where it can be used to detect sites of transcriptional activity and potentially sites of viral replication.

NIH immunologists have created a solution, Clearing-enhanced 3D (Ce3D), that can be used to make entire organs extremely transparent (top right panel). This allows the tissue to be imaged using advanced fluorescence microscopy techniques (bottom panel). Unlike current tissue clearing solutions, the Ce3D tissue clearing solution is robustly compatible with a variety of staining methods, and preserves tissue morphology and reporter fluorescence. Ce3D enabled microscopy provides unprecedented insight into the spatial organization of cells within intact organs.